




PHARMACEUTICAL 2022

BRISTOL MYERS SQUIBB CO
Rank 288 of 466





PHARMACEUTICAL 2022

BRISTOL MYERS SQUIBB CO Rank 288 of 466



The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 114% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 76%, being 2.1% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	33,262,000
Cost of Goods Sold	9,940,000
Intangible Assets	63,029,000
Liabilities, Current	21,868,000
Liabilities, Non-Current	46,939,000
Other Assets	6,974,000
Other Compr. Net Income	551,000
Other Expenses	10,387,000
Other Liabilities	4,501,000
Other Net Income	0
Other Revenues	46,385,000
Property and Equipment	6,049,000
Research and Development	11,354,000
Selling, General and Administrative Expense	7,690,000

Output Variable	Value in 1000 USD
Assets	109,314,000
Liabilities	73,308,000
Expenses	39,371,000
Revenues	46,385,000
Stockholders Equity	36,006,000
Net Income	7,014,000
Comprehensive Net Income	7,289,500
Economic Capital Ratio	76%